Genital Herpes News and Research

RSS
A new strategy to prevent herpes virus infections

A new strategy to prevent herpes virus infections

NanoViricides retires Series C Convertible Preferred Stock previously purchased by Seaside

NanoViricides retires Series C Convertible Preferred Stock previously purchased by Seaside

NanoViricides to advance influenza drug candidate with completed $5M funding

NanoViricides to advance influenza drug candidate with completed $5M funding

NanoViricides’ oral FluCide dramatically improves survival in animals with H3N2 influenza A

NanoViricides’ oral FluCide dramatically improves survival in animals with H3N2 influenza A

Strong antiviral antibody response observed in oral administration of Flucide

Strong antiviral antibody response observed in oral administration of Flucide

FDA clears Roche's automated type-specific herpes tests

FDA clears Roche's automated type-specific herpes tests

Oral FluCide drug candidates effective in reducing lung viral load: NanoViricides

Oral FluCide drug candidates effective in reducing lung viral load: NanoViricides

Declining rates of circumcision in US infant males could add billions to health care costs

Declining rates of circumcision in US infant males could add billions to health care costs

Orally effective FluCide anti-influenza drug candidate

Orally effective FluCide anti-influenza drug candidate

Genocea announces new data that supports novel approach for development of HSV-2 vaccine

Genocea announces new data that supports novel approach for development of HSV-2 vaccine

HIV drug resistance: an interview with Dr. Silvia Bertagnolio

HIV drug resistance: an interview with Dr. Silvia Bertagnolio

Maternal antiviral suppressive therapy may not be as effective as thought

Maternal antiviral suppressive therapy may not be as effective as thought

ViroPharma initiates maribavir Phase 2 program for CMV infections

ViroPharma initiates maribavir Phase 2 program for CMV infections

NanoViricides reports positive pre-IND meeting with USFDA for FluCide

NanoViricides reports positive pre-IND meeting with USFDA for FluCide

Common sexually transmitted bacterial infection more than doubles risk of HIV

Common sexually transmitted bacterial infection more than doubles risk of HIV

Infection with M. genitalium may double African women's HIV risk

Infection with M. genitalium may double African women's HIV risk

FDA confirms FluCide pre-IND meeting date with NanoViricides

FDA confirms FluCide pre-IND meeting date with NanoViricides

NanoViricides files FluCide pre-IND briefing document with the FDA

NanoViricides files FluCide pre-IND briefing document with the FDA

New NIST clinical SRM can help in accurate CMV detection and treatment

New NIST clinical SRM can help in accurate CMV detection and treatment

Study confirms condom use reduces risk of HIV infection by 78%

Study confirms condom use reduces risk of HIV infection by 78%